Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed sporadic or neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs)~  * Stage III or stage IV (metastatic) disease~* Measurable disease, defined as at least 1 tumor that is measurable in 2 dimensions on CT scan or MRI~PATIENT CHARACTERISTICS:~* Ejection fraction normal by echocardiogram or MUGA~* Serum creatinine normal for age OR creatinine clearance \> 60 mL/min~* SGPT \< 5 times upper limit of normal (ULN)~* Bilirubin \< 2.5 times ULN~* Absolute neutrophil count ≥ 1,500/mm\^3\*~* Hemoglobin ≥ 9.0 g/dL\*~* Platelet count ≥ 100,000/mm\^3\*~* ECOG performance status 0-2~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after completion of study treatment NOTE: \* Unsupported~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy for MPNST~* Prior surgical resection of MPNST allowed provided residual or recurrent measurable disease is present~* Recovered from toxic effects of all prior therapy~* At least 3 weeks since prior chemotherapy or biologic therapy for treatment of a plexiform neurofibroma, optical pathway tumor, or other NF1-associated tumor (in patients with NF1)~* At least 6 weeks since prior radiotherapy for treatment of a plexiform neurofibroma, optical pathway tumor, or other NF1-associated tumor (in patients with NF1)~* At least 4 weeks since prior radiotherapy to the area involved by MPNST~* No other concurrent growth factors (e.g., sargramostim \[GM-CSF\] or interleukin-11)~  * Concurrent epoetin alfa allowed

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy and local control by radiotherapy and surgery (Type: EXPERIMENTAL): Patients receive doxorubicin hydrochloride and ifosfamide (IA) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity. Patients then receive etoposide and ifosfamide (IE) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim (G-CSF) subcutaneously (SC) after each chemotherapy course. After recovery from chemotherapy, patients undergo radiotherapy and receive 2 more courses of IE during radiotherapy followed by 2 more courses of IA after completion of radiotherapy. Some patients may then undergo surgery.
- Chemotherapy and local control by surgery (Type: EXPERIMENTAL): Patients receive 2 courses of IA followed by 2 courses of IE as above. After recovery from chemotherapy, patients undergo surgery. After recovery from surgery, patients receive 2 more courses of IA followed by 2 more courses of IE in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).